CGM/CKM

PreclinicalBiologic

OOhio State University

CGM/CKM is one of 14 biologic programs targeting Polycystic Kidney Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polycystic Kidney DiseaseActive, not recruiting

Polycystic Kidney DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

19 competitors in Polycystic Kidney Disease

#DrugCompanyPhaseTrials

Actos

Takeda

Approved

—2

Rapamune

PPrism Pharmaceuticals

Farxiga

1 4

Afinitor

Novartis

Phase 3

1 5

Micardis

Boehringer Ingelheim

Phase 3

2 6

Samsca

Otsuka

Phase 3

2 7

Lanreotide Acetate

AAlbireo, an Ipsen Company

Phase 3

2 8

Metformin XR

AstraZeneca

Phase 3

1 9

Lesinurad

EEsperion Therapeutics, Inc.

Phase 2

1 10

Apresoline

Novartis

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

N/ARecruiting

Polycystic Kidney Disease

NCT06325644

Clinical

Trials by Indication[1]

Polycystic Kidney Disease1 trial

Well-Formulated Ketogenic Diet Polycystic Kidney Disease

Recruiting·OOhio State University·N/A·NCT06325644·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CGM/CKM. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CGM/CKM compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CGM/CKM. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ohio State University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: OOhio State University

CGM/CKM

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Polycystic Kidney Disease1 trial

References

Drug Info

Quick Facts

Related News